Keyword Analysis & Research: revolution medicines
Keyword Research: People who searched revolution medicines also searched
Search Results related to revolution medicines on Search Engine
-
Pipeline - Revolution Medicines
https://www.revmed.com/pipeline/
WebRevolution Medicines is building a deep pipeline in support of its focus on the development and delivery of novel targeted therapies to patients with RAS-addicted cancers.
DA: 25 PA: 71 MOZ Rank: 58
-
Investor Relations | Revolution Medicines
https://ir.revmed.com/
WebRevolution Medicines is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS companion inhibitors for use in combination treatment strategies.
DA: 44 PA: 82 MOZ Rank: 57
-
Revolution Medicines Completes Acquisition of EQRx
https://ir.revmed.com/news-releases/news-release-details/revolution-medicines-completes-acquisition-eqrx
WebREDWOOD CITY, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced it has closed its acquisition of EQRx, Inc.
DA: 32 PA: 17 MOZ Rank: 92
-
Revolution Medicines, Inc. to Acquire EQRx, Inc. in
https://www.globenewswire.com/news-release/2023/08/01/2715636/0/en/Revolution-Medicines-Inc-to-Acquire-EQRx-Inc-in-All-Stock-Transaction-to-Gain-More-Than-1-Billion-in-Additional-Capital.html
WebAug 1, 2023 · REDWOOD CITY, Calif. and CAMBRIDGE, Mass., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (“Revolution Medicines” or the “Company”) (Nasdaq: RVMD), a clinical-stage oncology...
DA: 19 PA: 32 MOZ Rank: 57
-
Revolution Medicines Doses First Patient in Phase 1/1b Clinical …
https://ir.revmed.com/news-releases/news-release-details/revolution-medicines-doses-first-patient-phase-11b-clinical-0
WebREDWOOD CITY, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced the first patient was dosed in its Phase 1/1b monotherapy clinical trial of RMC-9805, an oral, covalent, mutant-selective KRAS G12 D …
DA: 18 PA: 86 MOZ Rank: 15
-
Revolution Medicines Announces Publication on the Discovery of …
https://finance.yahoo.com/news/revolution-medicines-announces-publication-discovery-193400860.html
WebREDWOOD CITY, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with...
DA: 82 PA: 77 MOZ Rank: 45
-
Revolution Medicines | LinkedIn
https://www.linkedin.com/company/revolution-medicines/
WebREVOLUTION Medicines discovers and develops new drugs that harness the therapeutic potential of frontier oncology targets on behalf of cancer patients. Our innovative product …
DA: 86 PA: 3 MOZ Rank: 24
-
Revolution Medicines Completes Acquisition of EQRx - Yahoo …
https://finance.yahoo.com/news/revolution-medicines-completes-acquisition-eqrx-141000106.html
WebREDWOOD CITY, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers,...
DA: 33 PA: 3 MOZ Rank: 59
-
Revolution Medicines Doses First Patient in Phase 1/1b Clinical …
https://finance.yahoo.com/news/revolution-medicines-doses-first-patient-110000377.html
WebSep 19, 2023 · Revolution Medicines is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The company’s R&D pipeline comprises RAS (ON) Inhibitors designed to...
DA: 56 PA: 85 MOZ Rank: 90